Fathom Therapeutics

About Fathom Therapeutics

Atommap, established in 2023 and headquartered in New York City, is a computational drug discovery company operating at the intersection of quantum physics, artificial intelligence, and computation-driven design. The company was founded by CEO Huafeng Xu, Chief Computational Scientist Jesus Izaguirre, and Chief Technology Officer Yujie Wu. The leadership team brings a wealth of experience from previous roles at companies like Silicon Therapeutics, Roivant Discovery, D.E. Shaw Research, and Schrodinger, where they were instrumental in developing widely used software for molecular dynamics simulations (Desmond) and protein-ligand affinity prediction (FEP+). Dr. Xu, a PhD graduate from Columbia University, previously served as CTO of Silicon Therapeutics and Roivant Discovery, leading the development of computational platforms for drug discovery. The firm's core business revolves around its computational molecular design platform, which is engineered to accelerate the discovery of new therapeutic molecules. This platform integrates physics-based simulations, machine learning models, and high-performance computing to generate and assess molecular designs at an atomic level.